202 related articles for article (PubMed ID: 29892519)
1. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries.
von Moos R; Body JJ; Rider A; de Courcy J; Bhowmik D; Gatta F; Hechmati G; Qian Y
J Bone Oncol; 2018 Jun; 11():1-9. PubMed ID: 29892519
[TBL] [Abstract][Full Text] [Related]
2. A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe.
Body JJ; von Moos R; Rider A; Hallworth P; Bhowmik D; Gatta F; Hechmati G; Qian Y
J Bone Oncol; 2019 Feb; 14():100212. PubMed ID: 30627511
[TBL] [Abstract][Full Text] [Related]
3. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States.
Henry D; von Moos R; Body JJ; Rider A; De Courcy J; Bhowmik D; Gatta F; Hechmati G; Qian Y
Curr Med Res Opin; 2019 Mar; 35(3):375-381. PubMed ID: 30550358
[TBL] [Abstract][Full Text] [Related]
4. Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study.
Jakob A; Zahn MO; Nusch A; Werner T; Schnell R; Frank M; Hamm N; Däßler KU; Losem C; Welslau M; Hoevel P; Potthoff K
J Bone Oncol; 2022 Apr; 33():100420. PubMed ID: 35340302
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
6. Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe.
von Moos R; Lewis K; Massey L; Marongiu A; Rider A; Seesaghur A
Bone; 2022 Jan; 154():116243. PubMed ID: 34757213
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
8. Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16).
Ribi K; Thürlimann B; Schär C; Dietrich D; Cathomas R; Zürrer-Härdi U; von Briel T; Anchisi S; Bohanes P; Blum V; von Burg P; Mannhart M; Caspar CB; von Moos R; Mark M
BMC Cancer; 2021 Feb; 21(1):182. PubMed ID: 33607966
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates and other bone agents for breast cancer.
O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
[TBL] [Abstract][Full Text] [Related]
10. Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach.
Jacobson D; Cadieux B; Higano CS; Henry DH; Bachmann BA; Rehn M; Stopeck AT; Saad H
J Bone Oncol; 2022 Jun; 34():100423. PubMed ID: 35378840
[TBL] [Abstract][Full Text] [Related]
11. Physicians' preferences for bone metastases treatments in France, Germany and the United Kingdom.
Qian Y; Arellano J; Gatta F; Hechmati G; Hauber AB; Mohamed AF; Bahl A; von Moos R; Body JJ
BMC Health Serv Res; 2018 Jul; 18(1):518. PubMed ID: 29970078
[TBL] [Abstract][Full Text] [Related]
12. Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16).
Mark M; Thürlimann B; Ribi K; Schär C; Dietrich D; Cathomas R; Zürrer-Härdi U; von Briel T; Anchisi S; Bohanes P; Blum V; von Burg P; Mannhart M; Caspar CB; von Moos R
J Bone Oncol; 2020 Apr; 21():100273. PubMed ID: 31970055
[TBL] [Abstract][Full Text] [Related]
13. Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom.
Hechmati G; Hauber AB; Arellano J; Mohamed AF; Qian Y; Gatta F; Haynes I; Bahl A; von Moos R; Body JJ
Support Care Cancer; 2015 Jan; 23(1):21-8. PubMed ID: 24939674
[TBL] [Abstract][Full Text] [Related]
14. Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis.
Bozzo A; Deng J; Abbas U; Bhasin R; Deodat M; Wariach S; Sanger S; Axelrod D; Masrouha K; Turcotte R; Wilson D; Ghert M
Clin Orthop Relat Res; 2021 Sep; 479(9):2047-2057. PubMed ID: 33835092
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW
J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
[TBL] [Abstract][Full Text] [Related]
16. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.
D'Oronzo S; Coleman R; Brown J; Silvestris F
J Bone Oncol; 2019 Apr; 15():004-4. PubMed ID: 30937279
[TBL] [Abstract][Full Text] [Related]
17. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.
Bragstad S; Flatebø M; Natvig GK; Eide GE; Skeie GO; Behbahani M; Pedersen PH; Enger PØ; Skeie BS
J Neurosurg; 2018 Jul; 129(1):71-83. PubMed ID: 28820304
[TBL] [Abstract][Full Text] [Related]
18. Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.
Cadieux B; Coleman R; Jafarinasabian P; Lipton A; Orlowski RZ; Saad F; Scagliotti GV; Shimizu K; Stopeck A
J Bone Oncol; 2022 Apr; 33():100416. PubMed ID: 35242510
[TBL] [Abstract][Full Text] [Related]
19. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
Henry D; Vadhan-Raj S; Hirsh V; von Moos R; Hungria V; Costa L; Woll PJ; Scagliotti G; Smith G; Feng A; Jun S; Dansey R; Yeh H
Support Care Cancer; 2014 Mar; 22(3):679-87. PubMed ID: 24162260
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma.
Jeon HL; Oh IS; Baek YH; Yang H; Park J; Hong S; Shin JY
J Bone Miner Metab; 2020 Mar; 38(2):254-263. PubMed ID: 31673791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
